Since we do not know the etiology or pathogenesis of autoimmune gastritis nor have any treatment influencing its progression, the only way of reducing the gastric cancer risk in patients with autoimmune gastritis is endoscopic control until a gastrin antagonist becomes clinically available. The gene discussed is GAST; the disease is autoimmune gastritis.